Kidney Cancer (Renal Cell Carcinoma): Symptoms, Staging, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Kidney cancer comprises several histological subtypes, of which renal cell carcinoma (RCC) represents approximately 90% of cases. Clear cell RCC is the most common subtype (70-80%). Approximately 76,000 new US cases are diagnosed annually, with approximately 14,000 deaths. Incidental discovery on cross-sectional imaging has increased early-stage detection. Incidence is rising, associated with increased rates of obesity, hypertension, and diabetic kidney disease. RCC is 2 times more common in men than women. Kidney Cancer (Renal Cell Carcinoma): Symptoms, Staging, and Treatment is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Kidney Cancer (Renal Cell Carcinoma): Symptoms, Staging, and Treatment to help patients understand the condition, its causes, symptoms, and available treatment options.

Smoking doubles RCC risk. Obesity, hypertension, and chronic kidney disease each independently increase risk. Hereditary syndromes: VHL disease (clear cell RCC), hereditary papillary RCC (MET mutation), Birt-Hogg-Dube syndrome (FLCN mutation, chromophobe and oncocytoma), hereditary leiomyomatosis and RCC (FH mutation, aggressive papillary Type 2). Occupational exposures to cadmium, asbestos, and trichloroethylene confer additional risk. Analgesic nephropathy from prolonged NSAID or phenacetin use increases renal pelvis transitional cell carcinoma risk more than RCC. The causes of Kidney Cancer (Renal Cell Carcinoma): Symptoms, Staging, and Treatment are often multifactorial, involving a combination of genetic predisposition, environmental exposures, and lifestyle factors. In some cases, infectious agents, immune dysfunction, or metabolic imbalances may contribute. Risk factors vary but may include age, sex, family history, and pre-existing medical conditions. Understanding the causes guides prevention strategies and informs treatment choices.

The classic triad of hematuria, flank pain, and palpable abdominal mass occurs in fewer than 10% of RCC patients. Most tumors are now detected incidentally on imaging performed for other reasons. Paraneoplastic syndromes are more common in RCC than most other cancers: hypertension (renin secretion), polycythemia (erythropoietin), hypercalcemia (PTHrP), Stauffer syndrome (elevated liver enzymes without hepatic metastases), and amyloidosis. Metastatic symptoms include cough (pulmonary), bone pain (skeletal), headaches (CNS), and paraneoplastic fever. Symptoms of Kidney Cancer (Renal Cell Carcinoma): Symptoms, Staging, and Treatment can range from mild to severe and may develop gradually or appear suddenly. Common presentations include pain, inflammation, or functional impairment related to the affected system. Symptoms may fluctuate over time with periods of remission and exacerbation. Consult a healthcare provider if symptoms persist or worsen, as early diagnosis improves outcomes.

CT urography (renal mass protocol with pre-contrast, arterial, venous, and delayed phases) is the standard imaging modality. The Bosniak classification guides management of cystic renal masses (I-V, with IV and V requiring surgery). MRI is used for CT-indeterminate lesions or to assess venous thrombus extent. Percutaneous needle biopsy is appropriate for small (less than 3 cm) indeterminate lesions or suspected metastatic disease. Germline testing (VHL, FLCN, FH, MET) is recommended for bilateral or multifocal tumors, young patients, or positive family history. AJCC 8th edition TNM staging is used; IMDC score stratifies metastatic patients. Diagnosis of Kidney Cancer (Renal Cell Carcinoma): Symptoms, Staging, and Treatment typically involves a thorough clinical history, physical examination, and targeted investigations. Laboratory tests, imaging studies, or specialist referrals may be required to confirm the diagnosis. Accurate diagnosis is essential for appropriate management and prevents unnecessary treatment.

Localized RCC: partial nephrectomy (preferred for tumors up to 7 cm and amenable to nephron-sparing) or radical nephrectomy; active surveillance for small (less than 3 cm) lesions in older patients; thermal ablation (RFA or cryoablation) for small tumors in non-surgical candidates. Adjuvant pembrolizumab (KEYNOTE-564) for Stage II-III high-risk RCC reduces recurrence. Metastatic clear cell RCC: nivolumab plus ipilimumab (intermediate/poor risk); axitinib plus pembrolizumab, cabozantinib plus nivolumab, or lenvatinib plus pembrolizumab across risk groups; belzutifan or cabozantinib for VHL-mutant or subsequent lines. Non-clear cell: clinical trial enrollment recommended. Treatment of Kidney Cancer (Renal Cell Carcinoma): Symptoms, Staging, and Treatment is tailored to the individual and depends on severity and underlying cause. Options may include medications, lifestyle modifications, surgical interventions, or supportive therapies. Multidisciplinary care is often recommended for complex cases. The goal is to alleviate symptoms, slow disease progression, and improve quality of life.

Five-year survival by AJCC stage: Stage I approximately 81%, Stage II approximately 74%, Stage III approximately 53%, Stage IV approximately 8-12% (historical). With modern immunotherapy combinations for metastatic RCC, 5-year OS has improved substantially: approximately 42% for CheckMate 214 (nivolumab plus ipilimumab) for intermediate and poor risk patients. VHL-mutant and IMDC favorable-risk patients have the best outcomes. Sarcomatoid differentiation (present in approximately 20% of RCC) predicts aggressive behavior and poor prognosis but specifically high response rate to nivolumab plus ipilimumab. The prognosis for Kidney Cancer (Renal Cell Carcinoma): Symptoms, Staging, and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

Smoking cessation reduces RCC risk by approximately 30% within 5 years. Blood pressure control with antihypertensive therapy and weight management reduce modifiable risk factors. Patients with hereditary RCC syndromes (VHL, FLCN, FH, MET) require annual renal imaging surveillance starting in early adulthood. Belzutifan treats VHL disease-associated RCC and can delay surgical intervention. Avoidance of trichloroethylene, cadmium, and asbestos in occupational settings reduces exposure-related risk. No general population screening is recommended for RCC. Prevention strategies for Kidney Cancer (Renal Cell Carcinoma): Symptoms, Staging, and Treatment focus on reducing modifiable risk factors and promoting overall health. Lifestyle interventions such as a balanced diet, regular physical activity, and avoidance of tobacco and excessive alcohol are beneficial. Routine screening and early detection are important where treatment is more effective at early stages.

Go to the ER immediately for massive gross haematuria with clot retention causing urinary obstruction, spontaneous perirenal haemorrhage (sudden severe flank pain with haemodynamic instability — Wunderlich syndrome), or new acute limb weakness suggesting spinal cord compression from a vertebral metastasis. See a urologist urgently for any episode of painless gross haematuria (even a single episode without pain), an incidentally discovered renal mass on any imaging, or the classic triad of haematuria plus flank pain plus palpable abdominal mass. Routine: all hereditary RCC syndrome carriers (VHL, Birt-Hogg-Dube, hereditary leiomyomatosis and RCC, hereditary papillary RCC) require annual renal imaging starting in early adulthood. No general population RCC screening is recommended.